Sex: F
Vaccine: PPV
Symptoms: Demyelinating polyneuropathy, Electromyogram abnormal, Endotracheal intubation, Facial pain, Guillain-Barre syndrome
Clinical narrative: This is a literature case report. A 66-year old female with a past medical history of hypertension, hyperlipidemia, and gastroesophageal reflux disease presented to her local clinic on Jan2015 for an annual exam. She was on the cusp of retirement and was told by her physician to receive all the immunizations. She received the first dose of PCV13 in Jan2015 and then the second dose of PPSV23 in Aug2015. She then began to feel weakness in the knees in Sep2015 but dismissed it thinking it was mild arthritis. Few days later, she was unable to move her legs at all. She went to the ER in Oct2015 due to her immobility and was admitted because of severe hyponatremia on admission. After being stabilized and discharged from the hospital, she was given rehabilitation for what they assumed to be an idiopathic cause of immobility. Three days later, she came to the hospital from home on 11Nov2015 for worsening bilateral lower extremity weakness. The neurological examination at the time revealed grossly decreased bilateral muscle strength (< 1+) with abated or absent tendon reflexes of the lower limbs; muscle strength, reflexes and muscle tension remained normal in the upper limbs. The patient experienced loss of temperature sensation in distal extremities and symmetrical glove-and stocking-type pinprick sensations, but had normal proprioception and vibration senses. She also had prefrontal and bilateral facial pain with loss of touch and heat sensation; negative bilateral Babinski and Hoffman reflex; regular discriminative touch. Electromyography (EMG), nerve conduction velocity (NCV) on 18Nov2015 showed evidence of mixed axonal and demyelinating sensorimotor polyradiculopathy which has the poorest recovery of all GBS variants. She received two rounds of intravenous immunoglobulin therapy (IVIg) with a standard single IVIg dose = 0.4 g/kg body weight for five days. On 18Nov2015, eight weeks after the symptom onset, the review of the neurophysiology showed drastic improvement of peripheral nerve conduction. Her clinical symptoms also improved and the patient was discharged to further rehabilitation. On 26Nov2015, patient had respiratory failure and required intubation. She presented to the hospital for ventilator management due to chronic respiratory failure that developed with presumed Guillain-Barre syndrome (GBS). By Jan2016, patient became verbally unresponsive, unable to raise/move her forearms and legs but opened eyes when called and shrugged shoulder briefly to commands. She was given consultations for range of motion (ROM) exercises by physical therapy and speech therapy. After continued occupational therapy, physical and speech therapy, patient reported progressive improvement in motor function of upper extremities starting 24Jan2016. By Jul2016, patient's respiratory stabilized and was capped around the clock tolerating well on room air. The quadriparesis began improving with Lyrica 50 mg and daily physical therapy. By 03Nov2016, patient was able to sit up on a chair and respiratory failure completely resolved. Patient continues to improve on her muscular weakness but did express moving forward, she could tolerate more aggressive physical therapy. Discussion. Guillain Barre is an immune disorder resulting from autoimmune antibodies that cross-react with epitopes on peripheral nerves, leading to limb weakness. Early initiation of intravenous immunoglobulins (IVIg) or plasma exchange is of proven benefit especially in those with rapidly progressive weakness. Recently, IVIg has replaced plasma exchange in many treatment centers due to its convenience and availability. Hence, IVIg was administered over plasma exchange in this case. GBS is commonly linked to different infections, particularly Campulobacter Jejuni enteritis, however unwanted autoimmunity does not arise in most individuals (> 99%) exposed to C. jejuni. The major mechanism resulting in the autoimmunity by adjuvant vaccinations has been proposed to be due to the epitopes of a vaccine that initiates the development of antibodies and/or T cells that could cross-react with epitopes on myelin or axonal glycoproteins . This was the same mechanism that was seen in the remnant sample of the 1976 swine flu sample where antibodies to the ganglioside GM1 was not detected in subjects infected with or vaccinated against the H1N1 virus, but they were detected in a patient who developed GBS associated with the pandemic influenza vaccine. There were far fewer cases reported with GBS development after administration of the pneumococcal vaccine however. Streptococcus pneumonia cause invasive pneumococcal diseases (IPD), such as bacteraemia and meningitis, non-invasive infections, such as acute otitis media, sinusitis and mastoiditis, and pneumonia, which can be either invasive (bacteraemic pneumonia) or non-invasive (non-bacteraemic pneumonia). They are polysaccharide-encapsulated, gram positive, lancet-shaped organisms and pneumococcal vaccines rely on these capsules to induce a serotype-specific immune response. There are two types of pneumococcal vaccines, plain and conjugated, that have different mechanisms. The plain polysaccharide vaccines are T-cell independent antigens that cross-link B-cell receptors inducing immediate differentiation to plasma cells then antibodies. In contrast, conjugated vaccines elicit a T-cell dependent response. The polysaccharide conjugated to a carrier protein uses MHC class-II dependent response to present the carrier protein to carrierpeptide-specific helper T cells. This leads to enhancement of the B-cell immune response, so that the antibody response is of greater specificity and functionality. One paper indicated that the GM1-specific B cells pre-exist in peripheral blood and respond to T celldependent stimulation in Guillain-Barre syndrome and multifocal motor neuropathy. Thus, it can be inferred that the conjugated vaccine produces the enhanced B-cell immune response leading to autoimmune reaction to the peripheral nerves. Despite the adverse event highlighted in this case, overall incidence of serious adverse events ranged from 1.2% to 5.8% among persons vaccinated with PCV13, and 2.4% to 5.5% among persons vaccinated with PPSV23 1-6 months from initial dose. Common adverse reactions reported with the vaccines were pain, redness, fatigue, headache, chills, generalized muscle pain, and joint pain. The low numbers of reported GBS cases that were temporally associated with vaccinations, including PCV, indicates the benefits far greater than the risk. The PCV vaccine had significant efficacy in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease. Though randomized controlled studies have shown that plasma exchange and IVIg lead to quick recovery of GBS patients, concomitant use with other treatments such as ventilation, prevention of deep vein thrombosis and physical rehabilitation have been recommended and effective. Lower hospital mortality and improvement in survival have been documented for GBS patients receiving physiotherapy and high-intensity rehabilitation in the acute and sub-acute setting. Although there have been major strides in the management and treatment of Guillain-Barre syndrome, there are still many unresolved issues surrounding pathogenesis. All reported cases of GBS are thus crucial in the determination of the causes of GBS and achieving a good long-term outcome.; Sender's Comments: The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, as appropriate. The case will be reassessed if additional information becomes available.